

August 9, 2019

Listing Department
BOMBAY STOCK EXCHANGE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: **532321**

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: **CADILAHC**

Re: Press Release

Dear Sir,

We are forwarding herewith a copy of press release proposed to be published in the newspapers in the matter of unaudited financial results for the quarter ended on June 30, 2019 the same may please receive in order.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus Cadila registers Total income from Operations of Rs. 3496 Cr., up 21% in Q1

Ahmedabad, August 09, 2019

For the first quarter ended June 30, 2019, Zydus Cadila reported total income from operations of Rs. 3496 crores, up by 21% on a y-o-y basis. Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 632 crores, while the Net profit for the quarter stood at Rs. 304 crores.

The company's India business which comprises human formulations, consumer wellness and animal health business posted sales of Rs.1675 crores, up by 46% on a y-o-y basis. During the quarter, the company entered into a marketing alliance with SIFI, the Italian leader in the development of therapeutic solutions for treating ophthalmic disorders, to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI.

The company's business in the US posted sales of Rs. 1367 crores, up by 11% on a y-o-y basis. During the quarter, the company launched 8 new products in the US. The company filed 4 additional ANDAs with the USFDA and received 10 ANDA approvals, during the quarter. The company's business in the emerging markets of Asia, Africa and Latin America grew by 12% and posted sales of Rs. 220 crores.

Making progress in its research programme, during the quarter, the company announced the Phase III trials of Desidustat, an Investigational New Drug targeted at treating anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) patients. The company also announced the completion of the enrolment of patients in the EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in Non-Alcoholic SteatoHepatitis (NASH) across 20 clinical sites in the United States of America.
